MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR(TM) Sirolimus Drug Eluting Balloon

NYON, Switzerland, June 30, 2020 -- (Healthcare Sales & Marketing Network) -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. ... Devices, Interventional, Cardiology, Regulatory MedAlliance, SELUTION SLR, Sirolimus, Drug Eluting Balloon
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news